Company Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Pharmaceuticals

Delayed Nasdaq Stockholm 07:59:36 2024-03-28 am EDT 5-day change 1st Jan Change
6.68 SEK +1.21% Intraday chart for Egetis Therapeutics AB +1.21% +19.71%

Business Summary

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company's pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

Number of employees: 29

Sales per Business

SEK in Million2021Weight2022Weight Delta
Emcitate
97.3 %
16 40.9 % 22 97.3 % +39.92%
PledOx
2.7 %
23 59.1 % 1 2.7 % -97.34%

Sales per region

SEK in Million2021Weight2022Weight Delta
Other Countries
19.9 %
6 15.0 % 5 19.9 % -21.49%
France
17.3 %
3 7.6 % 4 17.3 % +33.52%
Spain
15.0 %
3 7.6 % 3 15.0 % +17.48%
United Kingdom
11.1 %
3 7.3 % 3 11.1 % -10.10%
Italy
9.7 %
-- 2 9.7 % -
Sweden
8.4 %
1 3.5 % 2 8.4 % +43.50%
Australia
8.4 %
-- 2 8.4 % -
Poland
7.5 %
-- 2 7.5 % -
Japan
2.7 %
23 59.1 % 1 2.7 % -97.34%

Managers

Managers TitleAgeSince
Chief Executive Officer 48 17-06-15
Director of Finance/CFO 45 17-12-30
Chief Tech/Sci/R&D Officer - 22-05-04
Chief Tech/Sci/R&D Officer 56 -
Chief Tech/Sci/R&D Officer 63 21-04-30
Chief Tech/Sci/R&D Officer 56 -
Chief Tech/Sci/R&D Officer 56 23-02-28
Chief Operating Officer 51 20-11-05
Chief Tech/Sci/R&D Officer 65 10-06-23
Director/Board Member 50 19-12-31

Members of the board

Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer 65 10-06-23
Director/Board Member 59 21-03-31
Director/Board Member 50 19-12-31
Chairman 73 21-03-31
Director/Board Member 63 16-12-31
Director/Board Member 63 16-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 292,571,459 212,443,237 ( 72.61 %) 0 72.61 %

Shareholders

NameEquities%Valuation
33,776,221 11.54 % 21 M kr
25,700,000 8.784 % 16 M kr
Avla Holding AB
6.039 %
17,668,330 6.039 % 11 M kr
Frazier Life Sciences Management LP
5.816 %
17,017,220 5.816 % 11 M kr
Handelsbanken Fonder AB
4.630 %
13,546,283 4.630 % 9 M kr
Flerie Invest AB
4.539 %
13,280,571 4.539 % 8 M kr
RegulaPharm AB
3.600 %
10,531,660 3.600 % 7 M kr
LINC AB
2.574 %
7,532,021 2.574 % 5 M kr
Unionen (Investment Management)
1.689 %
4,942,499 1.689 % 3 M kr
3,520,287 1.203 % 2 M kr

Company contact information

Egetis Therapeutics AB

Klara Norra Kyrkogata 26

111 22, Stockholm

+46 86 79 72 10

http://www.egetis.com
address Egetis Therapeutics AB(EGTX)

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.68 SEK
Average target price
13.12 SEK
Spread / Average Target
+96.48%
Consensus